ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
128.508,67
1,09%
S&P 500
5.127,79
1,26%
US Dollar vs BRL
5,09658
0,47%
Bitcoin
63.071,36
0,29%
Brent Oil
82,765
0,00%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. AnaptysBio Inc (ANAB)

  7. AnaptysBio Inc (ANAB) Notícias

ANAB

AnaptysBio (ANAB)

AnaptysBio Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:ANAB
DataHoraFonteTítuloCódigoCompanhia
24/04/202410:00PR Newswire (US)Actym Therapeutics Appoints Thomas Smart as CEONASDAQ:ANABAnaptysBio Inc
11/03/202417:41Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ANABAnaptysBio Inc
11/03/202417:36Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ANABAnaptysBio Inc
11/03/202417:19Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANABAnaptysBio Inc
29/02/202411:15GlobeNewswire Inc.Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual MeetingNASDAQ:ANABAnaptysBio Inc
14/02/202412:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ANABAnaptysBio Inc
31/01/202411:15GlobeNewswire Inc.Anaptys to Present at Guggenheim’s 6th Annual Biotechnology ConferenceNASDAQ:ANABAnaptysBio Inc
09/01/202421:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANABAnaptysBio Inc
27/11/202318:15GlobeNewswire Inc.Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa PharmaceuticalsNASDAQ:ANABAnaptysBio Inc
07/11/202318:15GlobeNewswire Inc.Anaptys Named a BioSpace 2024 Best Places to Work WinnerNASDAQ:ANABAnaptysBio Inc
02/11/202317:21Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANABAnaptysBio Inc
02/11/202317:15GlobeNewswire Inc.Anaptys Announces Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:ANABAnaptysBio Inc
01/11/202310:15GlobeNewswire Inc.Anaptys Announces Participation in November Investor ConferencesNASDAQ:ANABAnaptysBio Inc
11/10/202310:15GlobeNewswire Inc.Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV CongressNASDAQ:ANABAnaptysBio Inc
09/10/202309:43Dow Jones NewsAnaptys Sees Positive Trial Results for Imsidolimad Psoriasis TreatmentNASDAQ:ANABAnaptysBio Inc
09/10/202309:15GlobeNewswire Inc.Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25NASDAQ:ANABAnaptysBio Inc
09/10/202309:00GlobeNewswire Inc.Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)NASDAQ:ANABAnaptysBio Inc
02/10/202317:32Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ANABAnaptysBio Inc
18/09/202319:09Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ANABAnaptysBio Inc
18/09/202317:15GlobeNewswire Inc.AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of DirectorsNASDAQ:ANABAnaptysBio Inc
12/09/202310:15GlobeNewswire Inc.AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual SummitNASDAQ:ANABAnaptysBio Inc
07/08/202317:15GlobeNewswire Inc.AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:ANABAnaptysBio Inc
31/07/202315:27Dow Jones NewsAnaptysBio Shares Rise 11% After Jemperli Plus Chemotherapy Approved in U.S.NASDAQ:ANABAnaptysBio Inc
31/07/202314:34GlobeNewswire Inc.AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial CancerNASDAQ:ANABAnaptysBio Inc
30/05/202317:15GlobeNewswire Inc.AnaptysBio Announces Participation in Upcoming Investor ConferencesNASDAQ:ANABAnaptysBio Inc
11/05/202317:21Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ANABAnaptysBio Inc
11/05/202317:18Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ANABAnaptysBio Inc
11/05/202317:15GlobeNewswire Inc.AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline UpdateNASDAQ:ANABAnaptysBio Inc
02/05/202310:15GlobeNewswire Inc.AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP)NASDAQ:ANABAnaptysBio Inc
27/04/202317:23Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:ANABAnaptysBio Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:ANAB

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
HOOT4
HOTEIS OTHON PN
BOV
PRIO3
PETRORIO ON
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados